Carlsmed Inc (CARL) Stock Forecast & Price Target

Carlsmed Inc. demonstrates a strong financial outlook driven by significant growth in its surgeon customer base, which increased by approximately 70% year-over-year, leading to a top-line revenue of $13.1 million in the third quarter—representing a 98% growth. The company operates within a substantial addressable market, with an estimated $13.4 billion opportunity in the US lumbar fusion market, and anticipates expansion into cervical procedures by 2026, further increasing its total addressable market. Additionally, Carlsmed's gross margin of 75.9% exceeded forecasts, attributed to improved manufacturing cost management and inventory expense reductions, supporting its continued growth trajectory.

Carlsmed Inc. is facing a challenging financial outlook due to projected cervical revenue in FY26 falling short of estimates, with a reported estimate of $2.9 million compared to a higher expectation of $3.4 million. The company's growth potential is further hampered by risks such as slower adoption rates for its Aprevo technology among new surgeons, reduced overall growth in the spine market, and increasing operating expenses, which could all exacerbate financial losses. Additionally, competition from larger players in the spine market and potential reimbursement changes threaten to negatively impact pricing strategies, complicating Carlsmed's ability to gain market share and contribute to its ongoing EBITDA loss of $30.7 million.